-
(-)-Norepinephrine (+)-bitartrate Workflows
2026-09-15
Build more reproducible adrenergic assays and cardiovascular models with a workflow that separates salt-form calculations, receptor biology, and exposure timing. The approach also translates clinical vasopressor-conversion evidence into practical reporting and troubleshooting choices without treating a bedside ratio as an in vitro dose.
-
Fasudil (HA-1077) HCl: ROCK–Hippo Assay Logic
2026-09-15
Fasudil (HA-1077) HCl is a potent ROCK inhibitor for dissecting cytoskeletal signaling, cell migration, proliferation, and apoptosis. This article develops an assay framework that uses the quercetin–Hippo cataract study to clarify how ROCK perturbation can be tested without confusing mechanistic evidence with therapeutic proof.
-
17-AAG (Tanespimycin) Research Workflows
2026-09-14
Build more reliable HSP90 inhibition experiments with practical guidance for client-protein degradation, apoptosis profiling, and xenograft studies. The workflow also shows how lessons from a norovirus secretion study can improve assay controls without implying an unsupported antiviral use for 17-AAG.
-
EZH2, Autophagy, and Neuropathic Pain After BPA
2026-09-14
The reference study identifies an EZH2–mTOR–autophagy axis in anterior cingulate cortex microglia that intensifies neuroinflammation and neuropathic pain after brachial plexus avulsion. Its use of 3-MA as a pharmacological autophagy intervention supports autophagy as a functional mediator, while also illustrating why pathway-selective interpretation is essential.
-
Bafilomycin A1 in mRNA Trafficking Studies
2026-09-13
Bafilomycin A1 is a reversible V-ATPase inhibitor that can turn endosomal acidification into an experimentally testable variable. This article connects its mechanistic use to fluorinated-sorbitol polyplexes, showing how carefully timed perturbation can distinguish cellular uptake from endosomal escape and lysosomal loss.
-
C34 TLR4 Inhibitor: Workflow & Optimization
2026-09-12
C34 is a selective TLR4 inhibitor for separating TLR4-driven inflammation from TLR2 and TLR9 signaling in macrophage, enterocyte, tissue, and microglial assays. This guide converts published pathway evidence into practical dosing, controls, troubleshooting, and translational workflows for inflammatory signaling research.
-
BH3 Mimetics Clear Senescent Breast Cancer Cells
2026-09-12
The reference study shows that chemotherapy-induced senescence can create a delayed, therapeutically exploitable dependence on anti-apoptotic BCL-XL in TP53 wild-type breast cancer. Using cellular, genetic, and mouse-model experiments, the authors found that ABT-263 selectively eliminated a subset of senescent tumor cells, improved tumor regression, and extended survival after chemotherapy.
-
NSC 87877 for SHP2 Neuroinflammation Assays
2026-09-11
NSC 87877 provides a catalytic SHP2/SHP1 inhibition tool for connecting microglial NLRP3 biology with EGF–Ras–Erk signaling. This guide translates stroke-model findings into practical cell-based workflows, controls, dose selection, and troubleshooting strategies.
-
Auranofin Workflows for TrxR and Cancer Research
2026-09-11
Auranofin provides a practical way to perturb thioredoxin reductase, redox balance, apoptosis, and radiation response in cell-based research. This guide connects validated TrxR-oriented assays with the FOXO3/YAP metabolic framework described in recent HCC research, while separating evidence-backed findings from workflow recommendations.
-
SAR131675 VEGFR-3 Inhibitor: Assay Guide
2026-09-10
This scenario-based guide explains how SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor (SKU B2301), can be evaluated in viability, proliferation, migration, and cytotoxicity workflows. It links product-specific potency, selectivity, formulation, and safety limitations to practical assay decisions.
-
Tivozanib: Reading VEGFR Drug Responses Correctly
2026-09-10
Tivozanib and AV-951 offer a precise way to study VEGFR signaling pathway inhibition, but potency alone does not explain a cellular response. This evidence-based guide shows how to distinguish growth arrest from cell killing and design more interpretable oncology assays.
-
Deuterated Tetrazole CYP51 Inhibitor V23
2026-09-09
A 2025 European Journal of Medicinal Chemistry study describes V23, a deuterated tetrazole CYP51 inhibitor designed to improve fungal selectivity, metabolic stability, and activity against resistant pathogens. The compound showed broad in vitro activity, including against Aspergillus fumigatus, inhibited fungal phenotypic transitions and biofilms, displayed low mammalian-cell toxicity, and produced significant antifungal activity in vivo.
-
Oteseconazole (VT-1161) Candida Workflow
2026-09-09
Oteseconazole (VT-1161) enables concentration-controlled Candida susceptibility testing, resistant-isolate profiling, and mechanism-informed translational studies. Its fungal CYP51 selectivity supports focused antifungal experiments, while transporter findings caution researchers to separate target potency from broader drug-interaction risk.
-
JAK Inhibitors and Endothelial Cardiovascular Effects
2026-09-08
A comparative endothelial-cell study shows that JAK inhibitors can reduce inflammatory cytokine release without uniformly correcting adhesion, coagulation, or cell-survival abnormalities. The findings emphasize inhibitor-specific and concentration-dependent vascular effects that are important for interpreting cardiovascular risk in inflammatory disease research.
-
Multianimal MRI for Pancreatic Tumor Monitoring
2026-09-08
Kempinska et al. describe a four-chamber MRI workflow that images up to four KPC mice in one acquisition, improving the efficiency of tumor detection and longitudinal measurement. The protocol provides a practical framework for preclinical trial enrollment and for evaluating gemcitabine treatment response without replacing complementary pathological or molecular endpoints.